FCMI
AGRX

Foresite Capital Management II’s Agile Therapeutics AGRX Stock Holding History

Foresite Capital Management II’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-25
Closed -$428K – 30
2015
Q2 		$428K Sell
25
-205
-89% -$4.37M 0.15% 22
2015
Q1 		$4.26M Sell
230
-37
-14% -$648K 2.52% 13
2014
Q4 		$3.28M Buy
+267
New +$3.39M 2.25% 16

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Foresite Capital Management II's AGRX Position: Q3 2015 in Review

Foresite Capital Management II sold out of Agile Therapeutics (AGRX) in Q3 2015, closing a stake of 25 shares — an estimated $428K sold.

Foresite Capital Management II first reported a position in AGRX in Q4 2014 and held it in 3 quarters. The position peaked at $4.26M in Q1 2015. 45 funds tracked by Wall St. Rank hold AGRX as of Q3 2015.

  • Foresite Capital Management II reported no remaining Agile Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Foresite Capital Management II sold 25 Agile Therapeutics shares in Q3 2015, an estimated $428K.
  • Foresite Capital Management II first reported a position in Agile Therapeutics in Q4 2014 and held it in 3 quarters.
  • Foresite Capital Management II's Agile Therapeutics position peaked at $4.26M in Q1 2015.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q3 2015.

Based on Foresite Capital Management II's 13F filing for Q3 2015, filed 13 Nov 2015.